Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study.

Abstract

A prospective, multicenter, randomized study was conducted with human immunodeficiency virus (HIV)-infected patients who were successfully treated for acute cryptococcal meningitis, were receiving secondary prophylaxis, and were naive for antiretroviral therapy. Patients were randomized to continue or discontinue secondary prophylaxis when the CD4 cell count had increased to >100 cells/microL and an undetectable HIV RNA level had been sustained for 3 months. At a median of 48 weeks after randomization, there were no episodes of cryptococcal meningitis in either group.

• Authors: Asda Vibhagool, Somnuek Sungkanuparph, Piroon Mootsikapun, Ploenchan Chetchotisakd, Somsit Tansuphaswaswadikul, Chureeratana Bowonwatanuwong, Atiporn Ingsathit
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 36 Issue 10 Pg. 1329-31 (May 15 2003) ISSN: 1537-6591 [Electronic] United States
• PMID: 12746781 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-HIV Agents
• RNA, Viral

Topics

• AIDS-Related Opportunistic Infections (prevention & control)
• Adult
• Anti-HIV Agents (therapeutic use)
• Antibiotic Prophylaxis
• Antiretroviral Therapy, Highly Active
• CD4 Lymphocyte Count
• Female
• HIV
• HIV Infections (complications, drug therapy)
• Humans
• Male
• Meningitis, Cryptococcal (prevention & control)
• Prospective Studies
• RNA, Viral (analysis)